Phase 4 Lung Cancer Trial, Not Yet Recruiting NCT07567313 Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Condition: Lung Cancer
Back to Lung Cancer

Phase 4 Lung Cancer Trial, Not Yet Recruiting

NCT07567313
Not Yet Recruiting Phase 4

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • A diagnosis of squamous cell carcinoma of the lung, confirmed by a tissue or cell sample test.
  • The cancer has been assessed as stage IV (the most advanced stage) using a standard cancer staging system.
  • The person has completed 4 to 6 cycles of standard first-line chemotherapy combined with immunotherapy, and tests show the cancer has either partially shrunk or stayed stable.
  • The person is between 18 and 80 years old.
  • The person has a good general level of physical functioning, rated 0 or 1 on a standard scale used by doctors to measure daily activity and wellbeing (confirm with trial site).
  • Key organ functions are within acceptable ranges, including blood cell counts, liver function markers, kidney function, and protein levels in the blood (confirm with trial site for exact values).
  • The person and/or their family agrees to take part in the trial and signs a consent form.
  • No history of any other type of cancer.
  • No active infection at the time of joining.
  • Able to attend and cooperate with follow-up appointments during the study.
  • At least one measurable area of cancer that can be tracked using standard imaging guidelines.
  • Life expectancy is estimated to be more than 3 months.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • The cancer has a specific genetic change known as an EGFR sensitive mutation or an ALK gene translocation.
  • A history of allergic reactions to contrast dyes (used in scans) or chemotherapy drugs.
  • Having received any other cancer treatments beyond the standard first-line chemotherapy and immunotherapy.
  • Certain heart conditions, including significant heart rhythm problems, myocardial ischemia (reduced blood flow to the heart), or a past heart attack, or specific abnormal readings on a heart electrical test (ECG) (confirm with trial site for exact values).
  • Seriously abnormal blood clotting that cannot be corrected.
  • High blood pressure that remains poorly controlled (above certain levels) even after taking blood pressure medication.
  • Currently pregnant or breastfeeding.
  • A history of mental illness or misuse of psychiatric medications.
  • Brain metastases (cancer that has spread to the brain) that are causing symptoms.
  • Having an autoimmune disease (a condition where the immune system attacks the body's own tissues).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 4
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Registry
ClinicalTrials.gov
Start date
20 April 2026
Est. completion
1 January 2028

Primary endpoints

Progression-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov